Leading In Vitro Diagnostics Company Selects OmniComm''s(R) TrialMaster(R) Electronic Data Capture Solution
(firmenpresse) - FORT LAUDERDALE, FL -- (Marketwired) -- 09/17/14 -- OmniComm Systems, Inc. (OTCQB: OMCM), a global leading provider of clinical data management technology, is pleased to announce that a leading in vitro diagnostics (IVD) company has selected TrialMaster electronic data capture (EDC) to support its clinical evaluation of innovative IVD products for rapid identification and antibiotic susceptibility testing of infectious pathogens.
Because IVD trials are significantly different from drug or biologic studies, OmniComm has developed TrialMaster with specialized functionality that is supportive of IVD trials. TrialMaster''s intuitive user interface makes it an ideal choice for physicians and site personnel who may not be experienced in conducting IVD clinical evaluation studies. Another significant factor for the selection of TrialMaster was the ease of data capture directly from the IVD to TrialMaster. This integration is accomplished with OmniConnect™, a connectivity and integration framework that facilitates communication with other technology solutions.
"Given the unique way that IVD studies are conducted, the selection of TrialMaster demonstrates superbly the flexibility of our solution suite," said Kuno van der Post, senior vice president business development, OmniComm Systems, Inc. "TrialMaster enables fast study set up through its user friendly tools. This permits IVD sponsors and CROs timely date entry, enabling immediate business insights that can lead to rapid and high quality decisions."
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world''s pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit .
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company''s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company''s financial results can be found in the Company''s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.09.2014 - 06:34 Uhr
Sprache: Deutsch
News-ID 1303216
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
FORT LAUDERDALE, FL
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 130 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Leading In Vitro Diagnostics Company Selects OmniComm''s(R) TrialMaster(R) Electronic Data Capture Solution
"
steht unter der journalistisch-redaktionellen Verantwortung von
OmniComm Systems, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
